One Day Med Sp. z o.o.

The research at One Day Med Sp. z o.o. focuses on reducing the impact of atrial fibrillation by testing new rhythm‑control agents and assessing their safety and effectiveness.

• Evaluation of AP31969 for rhythm control
• Measurement of AF burden reduction
• Assessment of patient quality of life
• Long‑term cardiovascular outcomes

The cardiology team collaborates closely with local hospitals to bring innovative treatments to patients in Szczecin.

Studies at the site target advanced non‑small cell lung cancer with molecular alterations such as ALK‑positive and KRAS G12C, aiming to improve survival through targeted therapies and immunotherapy combinations.

• NVL‑655 versus alectinib in ALK‑positive NSCLC
• Olomorasib combined with pembrolizumab
• LY3537982 with platinum‑based chemotherapy
• Biomarker‑driven patient selection strategies

Oncology specialists at One Day Med Sp. z o.o. lead these trials, offering patients access to cutting‑edge cancer treatments.

The clinic is evaluating a novel topical therapy for recurrent herpes labialis, comparing its efficacy and tolerability to an established cream to shorten healing time and lower recurrence rates.

• Lipovir® Gel efficacy assessment
• Comparison with Zovirax® Cream
• Placebo‑controlled study design
• Patient‑reported symptom improvement

Residents of Szczecin interested in participating can contact One Day Med Sp. z o.o. for enrollment information.